LEO Pharma Launches Largest EADV Program with 5 Late-Breaking Abstracts and 23 Posters

LEO Pharma A/S, a global leader in medical dermatology based in Ballerup, Denmark, is set to reveal new clinical and real-world data from its product portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) Congress. This event, scheduled from September 25th to 28th in Amsterdam, Netherlands, will see LEO Pharma present five late-breaking presentations and 23 scientific posters detailing a range of skin conditions, marking the largest collection of data the company has ever shared at the EADV Congress.

Christophe Bourdon, CEO of LEO Pharma, expressed his excitement about the company's extensive participation in this year's EADV Congress. He highlighted the groundbreaking nature of the data to be shared, which underscores the company’s significant contributions to medical dermatology.

The first late-breaking presentation features Anzupgo® (delgocitinib) cream, showcasing data from a 24-week trial named DELTA FORCE. This study compared the efficacy and safety of the topical delgocitinib cream against oral alitretinoin capsules in adults suffering from severe chronic hand eczema (CHE). Another important presentation involves a matching-adjusted indirect comparison of delgocitinib and dupilumab for treating moderate to severe atopic hand eczema.

Further presentations include biomarker and efficacy data from a randomized clinical trial of delgocitinib cream in patients with frontal fibrosing alopecia. Additionally, real-world effectiveness results of tralokinumab in adult patients with head and neck atopic dermatitis, derived from the TRACE real-world evidence (RWE) study, will also be presented. Another notable study involves temtokibart, comparing its clinical and molecular responses in targeting IL-22RA1 against dupilumab in patients with moderate to severe atopic dermatitis.

Kreesten Meldgaard Madsen, Chief Development Officer at LEO Pharma, remarked on the importance of these presentations, emphasizing the comprehensive nature of the company's research portfolio and its commitment to developing innovative dermatological therapies.

LEO Pharma's agenda at the EADV Congress includes a variety of new research presentations, encore abstracts, and symposiums. The highlights include:

1. The DELTA FORCE trial, a 24-week phase 3 trial that compares the efficacy and safety of delgocitinib cream with oral alitretinoin capsules in adults with severe chronic hand eczema.
2. A matching-adjusted indirect comparison study of delgocitinib and dupilumab for moderate to severe atopic hand eczema.
3. A randomized clinical trial presenting biomarker and efficacy data for delgocitinib cream in patients with frontal fibrosing alopecia.
4. Real-world effectiveness studies on tralokinumab for atopic dermatitis, assessing both improvements in physician-assessed disease severity and patient-reported outcomes after up to nine months of treatment.
5. Comparison studies involving temtokibart and dupilumab, focusing on their clinical and molecular responses in treating moderate to severe atopic dermatitis.

The congress will also host three symposiums covering topics such as a new era in atopic dermatitis, the double burden of plaque psoriasis and obesity, and addressing chronic hand eczema.

Chronic hand eczema (CHE) is a prevalent skin disorder characterized by symptoms such as itch, pain, erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on the hands and wrists. It has a significant impact on patients' quality of life, affecting their ability to perform everyday activities and potentially impacting their careers and earning potential.

Atopic dermatitis, another focus of LEO Pharma’s research, is a chronic inflammatory skin disease marked by intense itching and eczematous lesions. The condition results from skin barrier dysfunction and immune dysregulation, leading to chronic inflammation driven by type 2 cytokines, including IL-13.

Psoriasis, affecting 125 million people globally, is a chronic systemic inflammatory disease that primarily manifests as itchy or painful raised scaly plaques on the skin. The most common form, plaque psoriasis, results from skin barrier cell proliferation and cytokine activation, leading to inflammation.

Through its extensive research and development, LEO Pharma aims to advance dermatological science and provide new hope to patients with challenging skin conditions, as highlighted by its diverse presentations at this year's EADV Congress.